Implantable, refillable device provides sustained delivery of anti-VEGF

TOKYO — An implantable device that provides sustained delivery of ranibizumab showed potential for optimal visual and anatomical outcomes, according to one speaker. The device, a port delivery system (PDS) produced by Genentech, addresses the need for successful treatment and reduced burden of frequent visits to the physician’s office, Roman Rubio, MD, head of ophthalmology at Genentech, said at the World Ophthalmology Congress. “It is a refillable, non-biodegradable, long-term drug delivery implant aimed at providing sustained drug release. It is placed in the pars plana beneath the conjunctiva using a (Read more...)

Full Story →